Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
17 hedge funds and large institutions have $26.8M invested in Calliditas Therapeutics AB American Depositary Shares in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
36% more capital invested
Capital invested by funds: $19.7M → $26.8M (+$7.04M)
31% more funds holding
Funds holding: 13 → 17 (+4)
23% less call options, than puts
Call options by funds: $1.26M | Put options by funds: $1.63M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.01M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$1.62M |
| 3 |
Optiver Holding
Amsterdam,
Netherlands
|
+$845K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$26K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$23.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$995K |
| 2 |
Renaissance Technologies
New York
|
-$294K |
| 3 |
IIM
Ironwood Investment Management
Boston,
Massachusetts
|
-$11.4K |
| 4 |
NFG
Next Financial Group
Houston,
Texas
|
-$1K |
CALT Hedge Fund Activity: Q4 2021 in Review
17 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q4 2021, worth a combined $26.8M — up 36% from $19.7M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CALT positions and 3 closed out — a net gain of 4 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $2.01M. The largest seller was Pentwater Capital Management, exiting entirely with an estimated $995K sold.
- 17 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q4 2021, up from 13 in Q3 2021.
- Funds reported $26.8M of Calliditas Therapeutics AB American Depositary Shares stock for Q4 2021, up 36% quarter-over-quarter.
- 7 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q4 2021 and 3 closed out, a net change of +4 holders.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q4 2021 was Tang Capital Management, an estimated $2.01M added.
- The largest Calliditas Therapeutics AB American Depositary Shares seller in Q4 2021 was Pentwater Capital Management, an estimated $995K sold.
Based on aggregated 13F filings for Q4 2021.